Q7Z3Y4 (Q7Z3Y4_HUMAN) Homo sapiens (Human)
Ig-like domain-containing protein UniProtKBInterProInteractive Modelling
236 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
21 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98M,HC-G99M,LC-S30bR] |
Heteromer V9HW68; | 6×EDO; | ||||
| Assess | ||||||
| Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98F,HC-G99M,LC-S30bR] |
Heteromer V9HW68; | 4×EDO; | ||||
| Assess | ||||||
| Crystal Structure of the anti-ErbB2 Fab2C4 |
Heteromer | 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98F,HC-G99M] |
Heteromer V9HW68; | 2×CL; 1×NA; 2×EDO; | ||||
| Assess | ||||||
| Crystal structure of the dimeric bH1-Fab variant [HC-Y33W,HC-D98M,HC-G99M] |
Heteromer V9HW68; | 2×CL; 1×NA; 1×EDO; | ||||
| Assess | ||||||
| Structure of Herceptin Fab without antigen |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of ABT-007 FAB fragment with the soluble domain of EPO receptor |
Heteromer P19235; Q6GMX6; | |||||
| Assess | ||||||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex |
Heteromer P04626; | 2×NAG; 1×NAG; | ||||
| Assess | ||||||
| CH1/Ckappa Fab mutant 15.1 |
Heteromer Q6GMX6; | 5×SO4; 4×EDO; | ||||
| Assess | ||||||
| Crystal structure of Fab DX-2930 |
Heteromer S6C4R2; | 1×CL; | ||||
| Assess | ||||||
| Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.1 Angstrom resolution |
Heteromer P03952; S6C4R2; | 3×EDO; | ||||
| Assess | ||||||
| Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.4 Angstrom resolution |
Heteromer P03952; S6C4R2; | 6×SO4; | ||||
| Assess | ||||||
| Murine 6A6 Fab in complex with humanized anti-Tissue Factor D3H44 Fab |
Heteromer G0YP42; P01857; P01863; | |||||
| Assess | ||||||
| CH1/Ckappa Fab based on Matuzumab |
Heteromer Q6GMX6; | |||||
| Assess | ||||||
| MATURE OXY-COPE CATALYTIC ANTIBODY WITH HAPTEN |
Heteromer P01857; | 5×CD; 1×HOP; | ||||
| Assess | ||||||
| Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain |
Heteromer P04626; P0DOX5; | 1×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of C-mannosyltransferase CeDPY19, in complex with acceptor peptide and bound to C… |
Heteromer P34413; | |||||
| Assess | ||||||
| Cryo-EM structure of C-mannosyltransferase CeDPY19, in ternary complex with Dol25-P-C-Man and accep… |
Heteromer P34413; | 1×IZU; | ||||
| Assess | ||||||
| Cryo-EM structure of C-mannosyltransferase CeDPY19, in complex with Dol25-P-Man and bound to CMT2-F… |
Heteromer P34413; | 1×IZY; | ||||
| Assess | ||||||
| PCSK9 complex with Fab33 |
Heteromer Q8NBP7; | |||||
| Assess | ||||||
| GPCR-Beta arrestin structure in lipid bilayer |
Heteromer P08172; P29066; P30518; V9HW68; | 1×2CU; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6o89.1.B | monomer | 0.79 | 89.50 | |||
| Assess | ||||||